Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2025-09-23 Capital/Financing Update
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
本公司透過子公司投資並取得New Alvogen Group Holding, Inc.全數股權
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about a corporate transaction where the company, through its subsidiary, acquired 100% equity of New Alvogen Group Holding, Inc. It includes specifics such as transaction date, price, parties involved, board approval, accounting firm opinions, and detailed terms of the deal including special shares and earn-out conditions. The content focuses on a capital acquisition and investment activity rather than financial results, management changes, or regulatory filings. The document length is 3821 characters, which is relatively short but contains substantive transaction details rather than just a notice or report publication announcement. Therefore, it fits best under Capital/Financing Update (CAP) as it reports on a significant financing and capital structure event.
2025-09-23 Chinese
公告本公司召開重大訊息記者會內容
M&A Activity Classification · 95% confidence The document is a company announcement from 美時化學製藥股份有限公司 (Meiji Chemical Pharmaceutical Co., Ltd.) regarding a significant acquisition transaction. It details the signing of a final agreement to acquire 100% of New Alvogen Group Holdings, Inc., including strategic rationale, expected financial impact, and management commentary. The document is a disclosure of a major corporate event (a merger/acquisition) and does not contain financial statements, audit information, or detailed financial results. It is not a full report but an announcement of a significant corporate transaction. Therefore, the appropriate classification is M&A Activity (TAR). The document length is short (1649 characters), consistent with an announcement rather than a full report.
2025-09-23 Chinese
本公司將召開法人說明會
Regulatory Filings Classification · 90% confidence The document is a short announcement (631 characters) about the company 1795 美時 holding a '法人說明會' (investor presentation or analyst meeting) on a specific date and time. It provides logistical details and mentions that full financial and business information can be found elsewhere. There is no detailed financial data or report content included. This fits the definition of an Investor Presentation (IP) announcement. However, since the document only announces the event and does not contain the presentation materials themselves, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the event, not the presentation content itself. The document is too short and does not contain the actual presentation or detailed financial data to be classified as IP. Therefore, the best fit is Regulatory Filings (RNS).
2025-09-23 Chinese
114年8月背書保證與資金貸與
Capital/Financing Update Classification · 90% confidence The document is a financial disclosure from a company named 美時, providing detailed figures on fund lending balances and endorsement guarantees for the current and previous months, as well as limits. The content is specific financial data related to capital and guarantees, but it is very brief (619 characters) and does not contain comprehensive financial statements or analysis. It appears to be a regulatory disclosure of financing-related information rather than a full report or announcement of a report. Given the nature of the data (fund lending balances, guarantees) and the absence of broader financial results or management discussion, the document best fits the category of Capital/Financing Update (CAP).
2025-09-10 Chinese
114年8月營業收入
Regulatory Filings Classification · 95% confidence The document is a revenue summary report for a company named 美時 for the month of August in the 114th year of the Republic of China calendar (equivalent to 2025). It provides monthly and cumulative net operating revenue figures, percentage changes compared to the previous year, and explanatory notes about accounting standards and reporting practices. The document is short (780 characters) and primarily presents summarized financial data without detailed financial statements or management discussion. It does not appear to be a full annual or interim report, nor an earnings release since it lacks key highlights or narrative commentary. It is more of a regulatory or public disclosure of summarized financial data. Given the short length and nature, it fits best as a Regulatory Filing (RNS) rather than a full financial report or announcement of a report publication.
2025-09-10 Chinese
114年08月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, general managers, and other executives. It includes data on shares held, increases, decreases, and trust shares, which is typical of insider shareholding disclosures. There is no indication of financial statements, earnings data, meeting materials, or legal proceedings. The content matches the definition of Director's Dealing, which reports personal share transactions by company directors and executives (insider trades). The document length is substantial and contains actual data, not just an announcement or certification. Therefore, the appropriate classification is Director's Dealing (DIRS).
2025-09-05 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.